Tumor Treating Fields Significantly Delay Intracranial Progression in NSCLC Patients Following Stereotactic Radiosurgery: Results of the METIS Trial

Tumor Treating Fields Significantly Delay Intracranial Progression in NSCLC Patients Following Stereotactic Radiosurgery: Results of the METIS Trial

The Phase 3 METIS trial demonstrates that Tumor Treating Fields (TTFields) following stereotactic radiosurgery significantly prolongs time to intracranial progression in NSCLC patients with brain metastases, without compromising neurocognitive function or quality of life, offering a promising new treatment paradigm.